Efgartigimod Efficacious, Safe for Primary Immune Thrombocytopenia

FRIDAY, Oct. 6, 2023 -- The first-in-class novel human immunoglobulin G1 Fc fragment, efgartigimod, is efficacious and safe for patients with chronic or persistent primary immune thrombocytopenia, according to a study published online Sept. 28 in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news